---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-073991"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:33:45.876722+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M

## Summary
- Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.
- PRV granted by FDA in Sept 2024 following approval of MIPLYFFA for Niemann-Pick disease type C.
- Unaudited cash, cash equivalents and investments at Mar 31, 2025 were $68.7M.
- Pro forma cash after net proceeds of $148.3M is $217M; CFO cites support for MIPLYFFA and OLPRUVA launches and celiprolol Phase 3 trial.

## SEC filing metadata
- accession: 0001193125-25-073991
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/0001193125-25-073991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000119312525073991/d938703d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-073991
- JSON: https://secwatch.observer/filing/0001193125-25-073991.json
- Plain text: https://secwatch.observer/filing/0001193125-25-073991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.